{"title":"Potential role of AhR in ischemia‑reperfusion injury and cancers: Focus on ferroptosis and lipid peroxidation signaling pathways (Review).","authors":"Zhihong Liao, Mingzhang Huang, Yuanqi Zhang, Siqi Huang, Wei Lei, Xiaorong Shui","doi":"10.3892/ijmm.2025.5597","DOIUrl":null,"url":null,"abstract":"<p><p>The aryl hydrocarbon receptor (AhR) is a pivotal ligand‑activated transcription factor that plays a crucial role in maintaining cellular redox homeostasis. The disruption of redox homeostasis in the etiology of numerous diseases primarily manifests as the accumulation of reactive species and the attenuation of the antioxidant defenses, leading to the progressive buildup of lipid peroxides. This phenomenon significantly contributes to the initiation and progression of diseases, such as atherosclerosis, cancer, diabetes and ischemia‑reperfusion injury. Ferroptosis is a form of cell death characterized by iron dependency and lipid peroxidation. The regulation of ferroptosis presents a promising therapeutic target for anticancer therapy and the prevention of neurodegenerative and cardiovascular diseases. AhR transcriptionally regulates downstream target genes, thereby modulating the biosynthesis and accumulation of bioactive compounds and the antioxidant defense mechanism. This process is intricately linked to lipid peroxide accumulation and subsequent ferroptosis. The present review provides an overview of the influence of AhR on lipid peroxidation and ferroptosis, the potential therapeutic targets, and the prospective application value of targeting the AhR to influence lipid peroxidation‑ferroptosis processes in tumor cells and ischemia‑reperfusion injury.</p>","PeriodicalId":14086,"journal":{"name":"International journal of molecular medicine","volume":"56 4","pages":""},"PeriodicalIF":5.8000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339175/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of molecular medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3892/ijmm.2025.5597","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/1 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
The aryl hydrocarbon receptor (AhR) is a pivotal ligand‑activated transcription factor that plays a crucial role in maintaining cellular redox homeostasis. The disruption of redox homeostasis in the etiology of numerous diseases primarily manifests as the accumulation of reactive species and the attenuation of the antioxidant defenses, leading to the progressive buildup of lipid peroxides. This phenomenon significantly contributes to the initiation and progression of diseases, such as atherosclerosis, cancer, diabetes and ischemia‑reperfusion injury. Ferroptosis is a form of cell death characterized by iron dependency and lipid peroxidation. The regulation of ferroptosis presents a promising therapeutic target for anticancer therapy and the prevention of neurodegenerative and cardiovascular diseases. AhR transcriptionally regulates downstream target genes, thereby modulating the biosynthesis and accumulation of bioactive compounds and the antioxidant defense mechanism. This process is intricately linked to lipid peroxide accumulation and subsequent ferroptosis. The present review provides an overview of the influence of AhR on lipid peroxidation and ferroptosis, the potential therapeutic targets, and the prospective application value of targeting the AhR to influence lipid peroxidation‑ferroptosis processes in tumor cells and ischemia‑reperfusion injury.
期刊介绍:
The main aim of Spandidos Publications is to facilitate scientific communication in a clear, concise and objective manner, while striving to provide prompt publication of original works of high quality.
The journals largely concentrate on molecular and experimental medicine, oncology, clinical and experimental cancer treatment and biomedical research.
All journals published by Spandidos Publications Ltd. maintain the highest standards of quality, and the members of their Editorial Boards are world-renowned scientists.